Mazdutide is one of the newer dual-agonist incretin compounds, part of the same
research wave as tirzepatide and retatrutide.
Chemical identity & structure.
Mazdutide is a synthetic peptide that acts as a dual agonist at the GLP-1
receptor and the glucagon receptor. It is based on a backbone related to
oxyntomodulin — a natural gut hormone that itself engages both of those
receptors — engineered for an extended half-life.
Mechanism of action.
The GLP-1 component contributes the appetite-suppression, insulin-secretion, and
gastric-emptying effects familiar from the GLP-1 class. The glucagon-receptor
component is hypothesized to add energy expenditure and to influence hepatic fat
and lipid metabolism. The balance between the two activities is the key research
question, as it is for all glucagon-containing multi-agonists.
Key research findings.
Mazdutide has been studied in clinical trials for weight management and glycemic
control, with published trial data reporting weight-loss and metabolic effects.
Much of its clinical development has been conducted with a focus on certain
regional markets.
The research / citation base.
Mazdutide is an investigational compound with a real clinical-trial program;
its regulatory status varies by jurisdiction and it is best described as
late-stage investigational rather than broadly approved. Its evidence base is
genuine clinical research, though shorter and less extensive than semaglutide's
or tirzepatide's.
In the phase 2 randomized, double-blind trial by Ji and colleagues (2023), 248 Chinese adults with overweight or obesity were assigned to once-weekly mazdutide 3 mg, 4.5 mg, 6 mg or matching placebo for 24 weeks (PubMed). In the phase 3 GLORY-1 trial (Ji and colleagues, 2025), 610 participants were randomly assigned to receive 4 mg of mazdutide, 6 mg of mazdutide, or placebo once weekly for 48 weeks (PubMed).
Research-grade material is supplied as a lyophilized powder.
Quality & sourcing notes.
A batch-specific COA should confirm identity by mass spectrometry and HPLC
purity. As with all in-demand incretin compounds, counterfeiting is a real
supply-chain risk; treat any vial without matching documentation as unverified.
*Research-use note: Educational summary of published research. Mazdutide is
investigational; this is research context only and not medical advice.*
